Navigation Links
Charleston Laboratories, Inc. Awarded a Qualifying Therapeutic Discovery Project (QTDP) Grant Under the U.S. Patient Protection and Affordable Care Act of 2010
Date:11/2/2010

CHARLESTON, S.C., Nov. 2, 2010 /PRNewswire/ -- Charleston Laboratories, Inc., an emerging specialty pharmaceutical company dedicated to reducing opioid-induced nausea and vomiting (OINV) in opioid pharmaceuticals, announced today that it was awarded a grant by the United States government under the Qualifying Therapeutic Discovery Project (QTDP) Program.  Charleston Laboratories received the maximum individual grant award to advance the development of its lead product, CL-108, for moderate to severe pain. CL-108 is currently being prepared for evaluation in an 1,100-patient Phase III clinical trial at investigative sites throughout the US, including major research universities in the US.

The QTDP grant program provides support for innovative projects that are determined by the U.S. Department of Health and Human Services to have reasonable potential to result in a new therapy, reduce health care costs, or significantly advance the goal of curing cancer. The QTDP program was created by Congress on May 21, 2010 under Section 48D of the Internal Revenue Code, as enacted under the Patient Protection and Affordable Care Act (PPACA).  

"Charleston is honored by this award," said Mr. Paul Bosse, Charleston Labs' CEO. "Receiving this grant acknowledges the potential of our company and, importantly, the clinical and economic benefits that our different opioid products can provide patients with debilitating pain."  

About Charleston Laboratories, Inc.

Charleston Laboratories Inc., headquartered in Charleston, SC, is a privately funded specialty pharmaceutical company developing and commercializing opioid drugs with minimal or no opioid-induced nausea and vomiting (OINV). Charleston Laboratories intends to enter into discovery and commercialization alliances with partners motivated to introduce novel pain therapies that eliminate or significantly reduce nausea and vomiting.

www.charlestonlabs.com


'/>"/>
SOURCE Charleston Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mobile Tour to Provide Prescription Help to the Uninsured in Charleston, S.C.
2. Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Second Quarter and First Six Months of Fiscal Year 2011
3. Caraco Pharmaceutical Laboratories, Ltd. Announces Change to Executive Team as G. P. Singh to Assume Position of CEO Effective November 1, 2010 and Update on Remediation Status
4. Roxane Laboratories, Inc. Announces the Launch of Losartan Potassium Tablets USP and Losartan Potassium and Hydrochlorothiazide Tablets
5. Caraco Pharmaceutical Laboratories, Ltd. Announces Appointment of Eddie Munson to Board of Directors
6. Novo Nordisk Inc. Announces Exclusive Agreement With Upsher-Smith Laboratories, Inc. to Market Vagifem® 10 mcg
7. Caraco Pharmaceutical Laboratories, Ltd. Announces G.P. Singh Sachdeva Is Appointed as Chief Operating Officer
8. Millennium Laboratories, Inc. Urges Medicare to Reconsider the 2010 Physician Reimbursement for Point-of-Care Urine Drug Screen Devices
9. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Flomax®
10. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Wellbutrin SR® Extended Release Tablets
11. Caraco Pharmaceutical Laboratories, Ltd. Receives Notice Regarding NYSE Amex Continued Listing Standards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... 18, 2017  Adaptive Sound Technologies, Inc. (ASTI), the leading ... with Hyatt Place Nashville/Downtown to deliver the best sleep ... therapy machines in over two hundred of its guest ... parts of having a great stay is sleeping well," ... Place Nashville/Downtown. "We,re pleased to be able to offer ...
(Date:1/18/2017)... , Jan. 18, 2017  Dermata Therapeutics, ... products to treat a variety of dermatological diseases, ... compound DMT210, in a Phase 2 acne rosacea ... to downregulate the proinflammatory cytokines in the skin ... acne rosacea. This clinical trial, ...
(Date:1/18/2017)... The report " Automated Breast Ultrasound System (ABUS) Market ... End User (Hospitals, Diagnostic Imaging Centers), Industry Analysis Report, Regional Outlook (U.S., ... , Germany , UK, France , ... , China , Japan , ... Saudi Arabia , UAE, South Africa ), ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... 19, 2017 , ... Fillers are known for building youthful ... that popular cosmetic fillers can enhance earlobes and rejuvenate an aging ... the MilfordMD Cosmetic Dermatology Surgery & Laser Center, in Milford, Penn. “People often ...
(Date:1/18/2017)... Baltimore, MD (PRWEB) , ... January 18, 2017 ... ... University of Maryland Fischell Department of Bioengineering are collaborating on a research project ... professor in bioengineering, the project seeks to use nanotechnology to control the disease ...
(Date:1/18/2017)... ... January 18, 2017 , ... PrideStaff, a national, ... Franchise Development, Paula Turner Pizarro, was recently featured on Fox Business Network's Worldwide ... of top business leaders from across the globe, provides viewers an opportunity to ...
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... ... technologies and development solutions for drugs, biologics and consumer health products, today announced ... be presenting at the upcoming WCBP Conference, to be held at the Mayflower ...
(Date:1/18/2017)... , ... January 18, 2017 , ... Floundering on New ... Month and the perfect time for a reset. The U.S. Apple Association agrees and ... combat many of the factors that contribute to heart disease. , The U.S. Apple ...
Breaking Medicine News(10 mins):